Study on the Efficacy and Safety of Tedizolid in Japanese Patients
Author Information
Author(s): Ishikawa Kazuhiro, Tsuda Yasumasa, Mori Nobuyoshi
Primary Institution: St. Luke’s International Hospital
Hypothesis
The study aimed to evaluate the safety of long-term Tedizolid use in Japanese patients, including those with hematological malignancies.
Conclusion
Tedizolid appears to be safe for long-term use, regardless of hematological malignancy status, with no major complications observed in this cohort.
Supporting Evidence
- Clinical cure rates were significantly higher in the non-HM group compared to the HM group (88.9% vs. 38.5%).
- The 90-day mortality rate differed notably between the HM and non-HM groups (69.2% and 3.7%).
- Despite 100% microbiological eradication, infection-related mortality rates were 3.7% in the non-HM and 38.5% in the HM group.
- No reported cases of optic neuritis, Clostridioides difficile colitis, or major bleeding.
Takeaway
Tedizolid is a medicine that helps treat infections and seems safe to use for a long time, even in patients with certain blood cancers.
Methodology
The study retrospectively reviewed medical records of patients aged 15 years and older who received Tedizolid treatment at St. Luke’s International Hospital between 2018 and 2023.
Potential Biases
The retrospective nature of the study may lead to underreporting of adverse events.
Limitations
The study is retrospective with a limited sample size and potential biases, making it difficult to fully evaluate adverse effects.
Participant Demographics
The median age of participants was 69 years, with 65% male.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website